▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

AscellaHealth Releases Q2 2024 Specialty & Rare Pipeline Digest™: Increased Approvals Signal Growing Demand and Utilization of Specialty Pharmaceuticals

AscellaHealth, a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions, t...

Business Wire

BERWYN, Pa.: AscellaHealth, a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming specialty and rare disease drug launches, cell and gene therapies (CGT), biosimilars and generics. This complimentary digital publication provides timely product updates to support the specialty drug market needs of stakeholders and decision-makers.

“The Q2 2024 Digest indicates a notable increase in specialty drug approvals and the introduction of additional cell and gene therapies compared to the previous quarter,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “This upward trend underscores the growing demand for specialty medications and highlights the essential role of AscellaHealth in addressing the needs of millions of individuals worldwide who are affected by complex, chronic conditions or rare diseases.”

This vast compilation of industry pipeline information exemplifies our commitment to being at the forefront of disseminating and sharing knowledge, providing valuable insights and data to support our partners, clients and the entire specialty pharmaceutical ecosystem.

“Recognized as an important resource for the industry, The Specialty & Rare Pipeline Digest™ captures key data demonstrating the rapid growth of the specialty pharmaceutical market,” states Dea Belazi, CEO, AscellaHealth. “As the number of approved drugs rises, so does the need for specialized care and innovative solutions to ensure patient access and adherence to treatment. These trends largely account for the growth of AscellaHealth as a single-source industry partner, providing end-to-end, global solutions which result in the streamlined commercialization of specialty drugs, cost savings for clients and an optimal treatment journey for patients and caregivers.”

AscellaHealth streamlines the pathway to successful drug commercialization and enhanced access by offering innovative solutions across the entire product lifecycle and care continuum. With a comprehensive suite of services, AscellaHealth guides life sciences clients through every stage of the commercialization process, from clinical trials and approval to transitioning patients onto approved therapies.

Access the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Dronus gets a strategic investment by Eni Next

Eni's VC company invest in the Italian drone company to develop new solutions for industrial plants monitoring

Technology Reply wins the 2024 Oracle Partner Awards - Europe South Innovation

Oracle recognizes Technology Reply’s ability to develop and deliver pioneering solutions through partnering with Oracle

25 Italian Startups Will Be Present at Expand North Star 2024

Scheduled for October, the world's largest startup event will bring together more than 2,000 exhibitors in Dubai, UAE

Most read

24 Promising Korean Tech Companies at TechCrunch Disrupt 2024

TechCrunch Disrupt 2024 will feature cutting-edge technology from 24 tech startups from South Korea. The Korea Pavilion is presented by Korea Trade-Investment…

Audit & Beyond Hosts Record Number of Attendees, Includes Launch of Powerful…

2024 AUDIT & BEYOND CONFERENCE — AuditBoard, the leading cloud-based platform transforming audit, risk, compliance, and ESG management, wrapped up…

University of Phoenix Launches New Career-Focused Skill Pathways in Practical…

In response to the growing demand for AI skills in the workforce, University of Phoenix is excited to announce the launch of new career-focused skill…

$16.4 Billion AI in Wound Care Market Industry Trends and Global Forecasts,…

The "AI in Wound Care Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Wound, Type of Acute Wound, Type of Chronic Wound,…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!